ATE169031T1 - Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor - Google Patents
Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptorInfo
- Publication number
- ATE169031T1 ATE169031T1 AT92910836T AT92910836T ATE169031T1 AT E169031 T1 ATE169031 T1 AT E169031T1 AT 92910836 T AT92910836 T AT 92910836T AT 92910836 T AT92910836 T AT 92910836T AT E169031 T1 ATE169031 T1 AT E169031T1
- Authority
- AT
- Austria
- Prior art keywords
- monoclonal antibodies
- antibodies against
- receptor
- specific monoclonal
- stem cell
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title abstract 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 abstract 2
- 102000055151 human KITLG Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68124591A | 1991-04-05 | 1991-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE169031T1 true ATE169031T1 (de) | 1998-08-15 |
Family
ID=24734435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92910836T ATE169031T1 (de) | 1991-04-05 | 1992-04-03 | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US5489516A (de) |
| EP (1) | EP0578774B1 (de) |
| JP (1) | JP3213314B2 (de) |
| AT (1) | ATE169031T1 (de) |
| CA (1) | CA2107553C (de) |
| DE (1) | DE69226431T2 (de) |
| DK (1) | DK0578774T3 (de) |
| ES (1) | ES2118820T3 (de) |
| WO (1) | WO1992017505A1 (de) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7144731B2 (en) * | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
| HU220234B (hu) * | 1989-10-16 | 2001-11-28 | Amgen Inc. | Eljárás stem sejtek működését befolyásoló faktorok előállitására |
| CA2107553C (en) * | 1991-04-05 | 2001-07-31 | Nancy Lin | Monoclonal antibodies to stem cell factor receptors |
| EP0548867A2 (de) * | 1991-12-23 | 1993-06-30 | Yeda Research And Development Co. Ltd. | Wasserlöslicher Stammzellenfaktor-Rezeptor |
| FR2700471B1 (fr) * | 1993-01-21 | 1995-04-07 | Pasteur Merieux Serums Vacc | Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus. |
| US5911988A (en) * | 1995-04-28 | 1999-06-15 | Bayer Corporation | Method for treating asthma using SCF antibody |
| US5824789A (en) * | 1995-06-07 | 1998-10-20 | Systemix, Inc. | Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof |
| DE19600589C1 (de) * | 1996-01-10 | 1997-01-16 | Univ Eberhard Karls | Antikörper A3C6E2 |
| US5928638A (en) * | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| JP2001505194A (ja) * | 1996-11-05 | 2001-04-17 | ブリストル―マイヤーズ・スクイブ・カンパニー | 分枝ペプチド・リンカー |
| US6017876A (en) | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
| US6737249B1 (en) * | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
| US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| SE511939C2 (sv) * | 1998-10-29 | 1999-12-20 | Henrik Willers | Förfarande och anordning för förankring av en boj |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| ATE510855T1 (de) | 2000-03-06 | 2011-06-15 | Univ Kentucky Res Found | Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen |
| US20050064587A1 (en) * | 2001-09-07 | 2005-03-24 | Lawrence Rosenberg | Pancreatic small cells and uses thereof |
| US20030175818A1 (en) * | 2002-03-15 | 2003-09-18 | Ross Amelia A. | Devices and methods for isolating and recovering target cells |
| US7754155B2 (en) * | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| WO2003091398A2 (en) | 2002-04-23 | 2003-11-06 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
| AU2003289116A1 (en) * | 2002-12-16 | 2004-07-09 | Canon Kabushiki Kaisha | Pattern identification method, device thereof, and program thereof |
| US20060003008A1 (en) | 2003-12-30 | 2006-01-05 | Gibson John W | Polymeric devices for controlled release of active agents |
| EP1916997B1 (de) * | 2005-08-05 | 2018-04-18 | Amgen Inc. | Pharmazeutische formulierungen aus stabilen wässrigen proteinen und ihre herstellung |
| TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| WO2008030538A2 (en) * | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
| PL3255061T3 (pl) | 2006-11-03 | 2021-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia |
| WO2008127735A1 (en) | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| PT2621519T (pt) | 2010-09-28 | 2017-10-04 | Aegerion Pharmaceuticals Inc | Polipéptido de fusão de leptina-abd com duração de ação melhorada |
| WO2012048276A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| WO2014018625A1 (en) | 2012-07-25 | 2014-01-30 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| EA035253B1 (ru) | 2013-03-15 | 2020-05-21 | Новартис Аг | Лекарственные конъюгаты антител |
| WO2015050959A1 (en) * | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
| CN105992816B (zh) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | 生物反应器中的细胞扩增 |
| CN106232800B (zh) | 2014-03-25 | 2020-07-03 | 泰尔茂比司特公司 | 介质的被动替代 |
| US10239943B2 (en) | 2014-05-23 | 2019-03-26 | Celldex Therapeutics, Inc. | Treatment of eosinophil or mast cell related disorders |
| WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
| WO2016154588A1 (en) | 2015-03-25 | 2016-09-29 | Children's Hospital Medical Center | Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| CN109415696A (zh) | 2016-05-25 | 2019-03-01 | 泰尔茂比司特公司 | 细胞扩增 |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| KR20190038537A (ko) | 2016-06-17 | 2019-04-08 | 마젠타 테라퓨틱스 인코포레이티드 | Cd117+ 세포의 고갈을 위한 조성물 및 방법 |
| SG10202102897PA (en) | 2017-01-20 | 2021-04-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| EP3656841A1 (de) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Zellexpansion |
| WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| EP4314244B1 (de) | 2021-03-23 | 2025-07-23 | Terumo BCT, Inc. | Zellerfassung und -erweiterung |
| KR20240115920A (ko) | 2021-12-16 | 2024-07-26 | 유니버시타트 바셀 | 세포 치료에 이용하기 위한 cd117의 식별 가능한 세포 표면 단백질 변이체 |
| US12152699B2 (en) | 2022-02-28 | 2024-11-26 | Terumo Bct, Inc. | Multiple-tube pinch valve assembly |
| EP4551601A1 (de) | 2022-07-07 | 2025-05-14 | Cimeio Therapeutics AG | Antikörper gegen cd117 |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965204A (en) * | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
| GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5081030A (en) * | 1989-04-25 | 1992-01-14 | The Johns Hopkins University | Release of cells from affinity matrices |
| US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| CA2107553C (en) * | 1991-04-05 | 2001-07-31 | Nancy Lin | Monoclonal antibodies to stem cell factor receptors |
-
1992
- 1992-04-03 CA CA002107553A patent/CA2107553C/en not_active Expired - Fee Related
- 1992-04-03 EP EP92910836A patent/EP0578774B1/de not_active Expired - Lifetime
- 1992-04-03 JP JP51001792A patent/JP3213314B2/ja not_active Expired - Fee Related
- 1992-04-03 WO PCT/US1992/002674 patent/WO1992017505A1/en not_active Ceased
- 1992-04-03 ES ES92910836T patent/ES2118820T3/es not_active Expired - Lifetime
- 1992-04-03 DK DK92910836T patent/DK0578774T3/da active
- 1992-04-03 DE DE69226431T patent/DE69226431T2/de not_active Expired - Fee Related
- 1992-04-03 AT AT92910836T patent/ATE169031T1/de not_active IP Right Cessation
-
1993
- 1993-01-29 US US08/011,078 patent/US5489516A/en not_active Expired - Lifetime
-
1994
- 1994-06-07 US US08/255,193 patent/US5922847A/en not_active Expired - Fee Related
-
1995
- 1995-05-24 US US08/449,139 patent/US5906938A/en not_active Expired - Fee Related
- 1995-06-05 US US08/462,638 patent/US5919911A/en not_active Expired - Fee Related
-
1999
- 1999-07-13 US US09/352,466 patent/US20020018775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1008827A1 (en) | 1999-05-21 |
| EP0578774A4 (en) | 1995-11-15 |
| DK0578774T3 (da) | 1999-04-26 |
| US5906938A (en) | 1999-05-25 |
| CA2107553C (en) | 2001-07-31 |
| US20020018775A1 (en) | 2002-02-14 |
| WO1992017505A1 (en) | 1992-10-15 |
| JP3213314B2 (ja) | 2001-10-02 |
| US5919911A (en) | 1999-07-06 |
| US5489516A (en) | 1996-02-06 |
| EP0578774B1 (de) | 1998-07-29 |
| DE69226431T2 (de) | 1999-04-22 |
| US5922847A (en) | 1999-07-13 |
| ES2118820T3 (es) | 1998-10-01 |
| CA2107553A1 (en) | 1992-10-06 |
| JPH06506833A (ja) | 1994-08-04 |
| EP0578774A1 (de) | 1994-01-19 |
| DE69226431D1 (de) | 1998-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE169031T1 (de) | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor | |
| ATE279517T1 (de) | Il-17 receptor | |
| NO20055446L (no) | Anvendelse av et interleukin-6 reseptorantistoff for fremstilling av en farmasoytisk blanding for behandlingav kronisk reumatoid artritt | |
| UA66750C2 (en) | Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors | |
| FI972945A0 (fi) | Antigeenien antamiseen soveltuvia koostumuksia | |
| MY122262A (en) | Lh-rh peptide analogues their uses and pharmaceutical compositions containing them | |
| UA29494C2 (uk) | Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція | |
| FI980341A0 (fi) | 2-oksi-indolijohdannaisia | |
| DE69824029D1 (de) | Bicyclische kinase inhibitoren | |
| DE69216532D1 (de) | Azidfreie gaserzeugende Zusammensetzungen | |
| EP0695171A1 (de) | Gonadotropin enthaltende gefriergetrocknete troepfen | |
| YU394A (sh) | Novi peptidi koji deluju kao antagonisti opijatskih receptora i postupci za njihovu izradu | |
| IL103510A0 (en) | Pharmaceutical compositions containing antibodies for causing immunosuppression | |
| YU13392A (sh) | ANTITELA NA HUMANI RECEPTOR ZA IgE | |
| ATE189122T1 (de) | Monoklonale anti-idiotypische anti - ca125 antikörper und sie enthaltende pharmazeutische zusammensetzung | |
| BR9806193A (pt) | Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm | |
| EP1186301A3 (de) | Monoklonale Antikörper die Flk-2 Rezeptoren erkennen, und die Isolierung primitiver hämatopoietischer Stammzellpopulationen | |
| TR199800152T1 (xx) | Endotelin Resept�r Antagonistleri | |
| DE59105603D1 (de) | Monoklonale antikörper gegen den interleukin 2-rezeptor. | |
| EA199700223A1 (ru) | Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции | |
| MY118946A (en) | Novel intermediates and their use to prepare n, n''- bridged bisindolylmaleimides | |
| ATE227122T1 (de) | Stabilisierte tablettenformulierung | |
| ATE252636T1 (de) | Klonierung und expression von dem beta app-c100 rezeptor | |
| DE59207362D1 (de) | Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
| DE69623464D1 (de) | Modifizierte kojibioside analoge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |